235 related articles for article (PubMed ID: 7797231)
1. Comparative analysis of the ability of leucocytes, endothelial cells and platelets to degrade the subendothelial basement membrane: evidence for cytokine dependence and detection of a novel sulfatase.
Bartlett MR; Underwood PA; Parish CR
Immunol Cell Biol; 1995 Apr; 73(2):113-24. PubMed ID: 7797231
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of the anti-inflammatory compounds heparin, mannose-6-phosphate, and castanospermine on degradation of the vascular basement membrane by leukocytes, endothelial cells, and platelets.
Bartlett MR; Cowden WB; Parish CR
J Leukoc Biol; 1995 Feb; 57(2):207-13. PubMed ID: 7852834
[TBL] [Abstract][Full Text] [Related]
3. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation.
Vlodavsky I; Eldor A; Haimovitz-Friedman A; Matzner Y; Ishai-Michaeli R; Lider O; Naparstek Y; Cohen IR; Fuks Z
Invasion Metastasis; 1992; 12(2):112-27. PubMed ID: 1399400
[TBL] [Abstract][Full Text] [Related]
4. Heparanase activity in cultured endothelial cells.
Godder K; Vlodavsky I; Eldor A; Weksler BB; Haimovitz-Freidman A; Fuks Z
J Cell Physiol; 1991 Aug; 148(2):274-80. PubMed ID: 1880155
[TBL] [Abstract][Full Text] [Related]
5. Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes.
Matzner Y; Bar-Ner M; Yahalom J; Ishai-Michaeli R; Fuks Z; Vlodavsky I
J Clin Invest; 1985 Oct; 76(4):1306-13. PubMed ID: 2997275
[TBL] [Abstract][Full Text] [Related]
6. Role of heparanase in platelet and tumor cell interactions with the subendothelial extracellular matrix.
Eldor A; Bar-Ner M; Yahalom J; Fuks Z; Vlodavsky I
Semin Thromb Hemost; 1987 Oct; 13(4):475-88. PubMed ID: 3321438
[TBL] [Abstract][Full Text] [Related]
7. Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix.
Ishai-Michaeli R; Eldor A; Vlodavsky I
Cell Regul; 1990 Oct; 1(11):833-42. PubMed ID: 2088528
[TBL] [Abstract][Full Text] [Related]
8. Sequential degradation of heparan sulfate in the subendothelial extracellular matrix by highly metastatic lymphoma cells.
Bar-Ner M; Kramer MD; Schirrmacher V; Ishai-Michaeli R; Fuks Z; Vlodavsky I
Int J Cancer; 1985 Apr; 35(4):483-91. PubMed ID: 3157649
[TBL] [Abstract][Full Text] [Related]
9. Translocation of active heparanase to cell surface regulates degradation of extracellular matrix heparan sulfate upon transmigration of mature monocyte-derived dendritic cells.
Benhamron S; Nechushtan H; Verbovetski I; Krispin A; Abboud-Jarrous G; Zcharia E; Edovitsky E; Nahari E; Peretz T; Vlodavsky I; Mevorach D
J Immunol; 2006 Jun; 176(11):6417-24. PubMed ID: 16709798
[TBL] [Abstract][Full Text] [Related]
10. Thrombin enhances degradation of heparan sulfate in the extracellular matrix by tumor cell heparanase.
Benezra M; Vlodavsky I; Bar-Shavit R
Exp Cell Res; 1992 Jul; 201(1):208-15. PubMed ID: 1612123
[TBL] [Abstract][Full Text] [Related]
11. Involvement of both heparanase and plasminogen activator in lymphoma cell-mediated degradation of heparan sulfate in the subendothelial extracellular matrix.
Bar-Ner M; Mayer M; Schirrmacher V; Vlodavsky I
J Cell Physiol; 1986 Aug; 128(2):299-306. PubMed ID: 2426287
[TBL] [Abstract][Full Text] [Related]
12. Cell surface localization of heparanase on macrophages regulates degradation of extracellular matrix heparan sulfate.
Sasaki N; Higashi N; Taka T; Nakajima M; Irimura T
J Immunol; 2004 Mar; 172(6):3830-5. PubMed ID: 15004189
[TBL] [Abstract][Full Text] [Related]
13. Soluble antigen induces T lymphocytes to secrete an endoglycosidase that degrades the heparan sulfate moiety of subendothelial extracellular matrix.
Fridman R; Lider O; Naparstek Y; Fuks Z; Vlodavsky I; Cohen IR
J Cell Physiol; 1987 Jan; 130(1):85-92. PubMed ID: 2433294
[TBL] [Abstract][Full Text] [Related]
14. Treatment of central nervous system inflammation with inhibitors of basement membrane degradation.
Parish CR; Hindmarsh EJ; Bartlett MR; Staykova MA; Cowden WB; Willenborg DO
Immunol Cell Biol; 1998 Feb; 76(1):104-13. PubMed ID: 9553782
[TBL] [Abstract][Full Text] [Related]
15. Degranulating mast cells secrete an endoglycosidase that degrades heparan sulfate in subendothelial extracellular matrix.
Bashkin P; Razin E; Eldor A; Vlodavsky I
Blood; 1990 Jun; 75(11):2204-12. PubMed ID: 1693299
[TBL] [Abstract][Full Text] [Related]
16. Human platelet heparanase: purification, characterization and catalytic activity.
Freeman C; Parish CR
Biochem J; 1998 Mar; 330 ( Pt 3)(Pt 3):1341-50. PubMed ID: 9494105
[TBL] [Abstract][Full Text] [Related]
17. Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plasminogen activators.
Korner G; Bjornsson TD; Vlodavsky I
J Cell Physiol; 1993 Mar; 154(3):456-65. PubMed ID: 8436596
[TBL] [Abstract][Full Text] [Related]
18. An iminosugar-based heparanase inhibitor heparastatin (SF4) suppresses infiltration of neutrophils and monocytes into inflamed dorsal air pouches.
Sue M; Higashi N; Shida H; Kogane Y; Nishimura Y; Adachi H; Kolaczkowska E; Kepka M; Nakajima M; Irimura T
Int Immunopharmacol; 2016 Jun; 35():15-21. PubMed ID: 27015605
[TBL] [Abstract][Full Text] [Related]
19. Specific degradation of subendothelial matrix proteoglycans by brain-metastatic melanoma and brain endothelial cell heparanases.
Marchetti D
J Cell Physiol; 1997 Sep; 172(3):334-42. PubMed ID: 9284953
[TBL] [Abstract][Full Text] [Related]
20. Degradation of basement membrane by prostate tumor heparanase.
Kosir MA; Wang W; Zukowski KL; Tromp G; Barber J
J Surg Res; 1999 Jan; 81(1):42-7. PubMed ID: 9889056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
